EMERGENCY:Acute severe dystonia or status dystonicus —call040-46324365immediately — 24 hours, 7 days— 24/7
Neuroacanthocytosis: A Group of Rare Genetic Movement Disorders — and Why the Blood Smear Matters
Neuroacanthocytosis refers to a group of rare inherited neurological disorders characterised by abnormal red blood cells (acanthocytes) and progressive movement disorders. These conditions primarily affect the basal ganglia, leading to chorea, dystonia, behavioural changes, and cognitive decline. Although rare, recognising neuroacanthocytosis is critical, as it is often misdiagnosed as other movement disorders such as Huntington's disease.
Movement Disorders · Rare Genetic Neurodegeneration
Prevalence less than 1–5 per million
Chorea-Acanthocytosis · McLeod Syndrome · HDL2 · PKAN
Movement Disorders · Neurology · Genetics · Cardiology
Peripheral blood smear for acanthocytes · Genetic testing
Cardiomyopathy and arrhythmia — cardiac monitoring is essential
Neuroacanthocytosis is an umbrella term for a group of rare inherited neurological disorders in which progressive degeneration of the basal ganglia — producing chorea, dystonia, psychiatric symptoms, and cognitive decline — occurs together with abnormally shaped red blood cells called acanthocytes (cells with thorny, spike-like projections) seen on the peripheral blood smear. The four core subtypes — Chorea-Acanthocytosis (VPS13A), McLeod Syndrome (XK), Huntington's Disease-Like 2 (JPH3), and PKAN (PANK2) — each have a distinct gene and a distinct inheritance pattern. Neuroacanthocytosis is frequently misdiagnosed as Huntington's Disease for years before the peripheral blood smear is examined for acanthocytes. McLeod Syndrome additionally carries a serious risk of dilated cardiomyopathy and arrhythmia that requires mandatory cardiac monitoring at KIMS Neuroscience, Hyderabad.
- What it is
- An umbrella term for a group of rare inherited disorders combining progressive basal ganglia degeneration (chorea, dystonia, psychiatric and cognitive decline) with thorny red blood cells called acanthocytes on the peripheral blood smear.
- Four core subtypes
- Chorea-Acanthocytosis (VPS13A) · McLeod Syndrome (XK) · Huntington's Disease-Like 2 (JPH3) · PKAN (PANK2). Each has a distinct inheritance pattern and a distinct gene.
- Most diagnostic clue
- Peripheral blood smear for acanthocytes — a simple, inexpensive microscopic test. KIMS communicates the clinical suspicion to the haematology lab so the smear is actively examined for acanthocytes (they can be missed on a routine smear).
- Frequently misdiagnosed as
- Huntington's Disease. Any patient with a Huntington's-like syndrome and a negative HTT genetic test should be reassessed for neuroacanthocytosis at KIMS.
- McLeod Syndrome cardiac risk
- Dilated cardiomyopathy and life-threatening arrhythmias affect McLeod patients (X-linked, almost exclusively males). ECG, echocardiogram, and 24-hour Holter monitoring are mandatory at diagnosis and on follow-up.
- Specific clinical flag
- Involuntary tongue-thrusting and self-injurious lip or tongue biting points strongly to chorea-acanthocytosis. Elevated serum CK without obvious muscle disease is another flag.
- Contact KIMS
- 040-44885000 · Genetic panel (VPS13A, XK, JPH3, PANK2) · Chorein immunoblotting · Cardiac monitoring programme · No referral required
| Fact | Details |
|---|---|
| Definition | Rare inherited neurodegenerative syndromes combining basal ganglia degeneration with acanthocytes on the peripheral blood smear · Prevalence less than 1–5 per million |
| Four subtypes | Chorea-Acanthocytosis (autosomal recessive, VPS13A) · McLeod Syndrome (X-linked, XK) · HDL2 (autosomal dominant, JPH3) · PKAN (autosomal recessive, PANK2) |
| Onset | Typically age 20–50 · Progressive chorea, dystonia, psychiatric symptoms, cognitive decline · Often misdiagnosed as Huntington's, Parkinson's, or primary psychiatric illness for years |
| Diagnostic pathway at KIMS | Peripheral blood smear for acanthocytes · Serum CK · Brain MRI (caudate and putamen atrophy) · Genetic panel · Chorein immunoblot · EMG and nerve conduction |
| McLeod Syndrome — cardiac | Cardiomyopathy and arrhythmia can cause sudden death · Mandatory ECG, echocardiogram, 24-hour Holter monitoring at diagnosis and follow-up · Cardiology co-management at KIMS |
| Distinguishing from Huntington's | Acanthocytes on smear · Different genes (not HTT) · Orolingual dystonia with self-biting (chorea-acanthocytosis) · Peripheral neuropathy · Elevated CK |
| Treatment | Tetrabenazine for chorea · Botulinum toxin for orolingual and focal dystonia · Antiepileptics for seizures · SSRIs for OCD and depression · DBS considered in refractory cases · Cardiac management in McLeod |
| Genetic counselling | Inheritance pattern differs by subtype — counselling individualised to the confirmed mutation · Family testing and family planning advice offered at KIMS |
About This Condition
What Is Neuroacanthocytosis?
Neuroacanthocytosis the name alone tells you the two defining features. Neuro for the neurological problems these conditions produce. Acanthocytosis for the abnormal red blood cells found in the blood red cells with thorny, irregular spike like projections on their surface, called acanthocytes from the Greek acantha meaning thorn.
Neuroacanthocytosis is not one disease. It is an umbrella term for a group of rare, inherited genetic conditions that share two key features these abnormally shaped red blood cells in the circulation, and progressive degeneration of the basal ganglia the deep brain structures that coordinate movement, behaviour, and cognition. The result is a combination of movement disorder, psychiatric symptoms, cognitive decline, and in some subtypes, cardiac and muscular complications.
The neuroacanthocytosis syndromes are exceptionally rare, with an estimated prevalence of less than 1 to 5 per million for each disorder. The four core subtypes are chorea-acanthocytosis, McLeod syndrome, Huntington’s Disease-Like 2 (HDL2), and Pantothenate Kinase-Associated Neurodegeneration (PKAN) — each described in the clinical classification section below. PKAN also has a dedicated condition page at KIMS: /conditions/neurodegenerative-disorders/pkan/
Because they are so rare, and because they mimic more common conditions, neuroacanthocytosis syndromes are regularly misdiagnosed. Huntington's Disease is the major disorder misdiagnosed in patients with neuroacanthocytosis a misdiagnosis that has profound implications, because the two conditions have completely different genetic causes, inheritance patterns, and family implications.
At KIMS Neuroscience, Hyderabad, our movement disorders team considers neuroacanthocytosis in the differential diagnosis of any young or middle aged patient with chorea, progressive behavioural change, or unexplained basal ganglia disease and performs the peripheral blood smear and genetic testing needed to confirm or exclude it.
Book a Consultation
Speak directly with our specialist team. No referral required. Monday to Saturday.
040-44885000International enquiries: info@kimsneurosciences.comThe Four Core Neuroacanthocytosis Syndromes
Chorea Acanthocytosis (ChAc) — The Most Clinically Distinctive Subtype
Chorea acanthocytosis is caused by mutations in the VPS13A gene and is inherited in an autosomal recessive pattern. It typically begins in the 20s to 40s and is distinguished by one of the most striking and clinically specific symptom combinations in all of movement disorder medicine:
1. Orolingual dystonia with self mutilation involuntary tongue thrusting and lip biting movements that cause progressive damage to the lips, tongue, and inside of the mouth. This feature a patient who involuntarily bites their own tongue and lips to the point of injury is so characteristic of chorea acanthocytosis that it is effectively a bedside diagnostic clue.
2. Chorea involuntary, flowing, dance like movements of the limbs and trunk, similar to Huntington's Disease
3. Progressive cognitive decline executive dysfunction and behavioural changes resembling Frontotemporal Dementia in character
4. Psychiatric symptoms personality change, disinhibition, obsessive compulsive features, depression
5. Seizures common, often one of the earlier features
6. Peripheral neuropathy with elevated serum creatine kinase CK, reflecting muscle involvement
7. Swallowing difficulties as orolingual dystonia progresses
Because of the prominent orofacial dyskinesias and common treatment of the associated psychiatric disorder with neuroleptics, tardive dyskinesia is often considered in the initial differential diagnosis. This further delays correct diagnosis.
McLeod Syndrome — The X Linked Subtype with Cardiac Risk
McLeod Syndrome is caused by mutations in the XK gene on the X chromosome. Unlike the other neuroacanthocytosis syndromes, it is X linked recessive almost exclusively affecting males. There are approximately 150 confirmed cases of McLeod syndrome worldwide making it among the rarest movement disorders in existence.
The clinical features resemble chorea acanthocytosis chorea, cognitive decline, psychiatric symptoms but McLeod syndrome has one uniquely dangerous feature cardiomyopathy and cardiac arrhythmia. The heart muscle becomes enlarged and weakened, and serious cardiac arrhythmias can develop. Cardiac complications are a cause of sudden death in McLeod syndrome. Every patient with McLeod syndrome requires regular cardiac assessment and monitoring echocardiography and Holter monitoring as a routine part of their care.
McLeod syndrome is also important for blood transfusion medicine affected individuals have the McLeod blood group phenotype and require specially matched blood for transfusions.
Huntington's Disease Like 2 (HDL2)
HDL2 is caused by a trinucleotide repeat expansion in the JPH3 gene. It is clinically almost indistinguishable from Huntington's Disease causing chorea, cognitive decline, psychiatric symptoms, and a progressive course. It is autosomal dominant, like HD. The key distinguishing feature is the gene involved and the presence of acanthocytes on the blood smear.
HDL2 is more common in individuals of African ancestry. Genetic testing is the only reliable way to distinguish HDL2 from Huntington's Disease once acanthocytes have been identified.
Pantothenate Kinase-Associated Neurodegeneration (PKAN) — The Most Common NBIA Disorder and the Fourth Core Neuroacanthocytosis Syndrome
Pantothenate Kinase-Associated Neurodegeneration (PKAN) is the most common form of Neurodegeneration with Brain Iron Accumulation (NBIA) and the fourth core syndrome in the neuroacanthocytosis group. It is caused by mutations in the PANK2 gene on chromosome 20, which encodes pantothenate kinase 2 — an enzyme essential for coenzyme A (CoA) biosynthesis from pantothenate (vitamin B5). Loss of PANK2 function leads to a failure of CoA production in the mitochondria of the globus pallidus, resulting in accumulation of cysteine-containing compounds and, subsequently, chelation and deposition of iron in the basal ganglia. The hallmark MRI finding — the “Eye of the Tiger” sign — reflects this iron deposition: bilateral T2 hypointensity of the globus pallidus (dark from iron accumulation) with a central area of hyperintensity (from tissue oedema or necrosis), producing an appearance that, in cross-section, resembles a tiger’s eye.
PKAN is inherited in an autosomal recessive pattern — both parents must be carriers of a PANK2 mutation for a child to be affected. In India, where consanguineous marriages are more prevalent particularly in South India and Telangana, the carrier frequency for PANK2 mutations is higher and PKAN accounts for the majority of NBIA cases seen at specialist centres including KIMS.
Two clinical forms are recognised:
Classic PKAN: Onset in the first decade of life, usually before age 6. Rapidly progressive. Dystonia — typically beginning in the feet and legs — is the dominant feature, causing an abnormal gait that progresses to inability to walk within years. Dysarthria, choreoathetosis, and postural instability follow. Many children require a wheelchair by early adolescence. Pigmentary retinal degeneration is present in approximately 25% of classic PKAN cases. Cognitive impairment and intellectual disability are common.
Atypical PKAN: Later onset, typically in the second or third decade of life. Slower progression over decades rather than years. Prominent speech and language difficulties — palilalia (repetitive speech), stuttering, dysarthria. Psychiatric features including personality change, impulsivity, and mood disturbance. Gait difficulty and dystonia, but generally milder than classic PKAN at the same disease duration. Cognitive decline in later stages.
A clinical note on acanthocytes in PKAN: Unlike chorea-acanthocytosis and McLeod syndrome, acanthocytes are present in only approximately 8–10% of PKAN patients — a significantly lower proportion. A negative peripheral blood smear does not exclude PKAN. When PKAN is suspected clinically — particularly in a child with early-onset dystonia and an MRI showing the Eye of the Tiger sign — PANK2 genetic testing should proceed regardless of the smear result.
Treatment for PKAN is currently symptomatic: trihexyphenidyl and other anticholinergic agents for dystonia; botulinum toxin injections for focal dystonic postures; tetrabenazine or deutetrabenazine for choreiform components; antiepileptics for seizures. Iron chelation with deferiprone has been studied in clinical trials — the TIRCON trial (2013) did not demonstrate significant clinical benefit over 18 months, though some studies show slowing of MRI iron accumulation. Pantothenate supplementation at very high doses has been tried without convincing clinical evidence. Deep brain stimulation of the globus pallidus interna (GPi) has shown meaningful symptom reduction in published series, particularly for the dystonic features, and is available at KIMS. There is no disease-modifying treatment that arrests PKAN progression.
PKAN has its own dedicated condition page at KIMS Neuroscience — /conditions/neurodegenerative-disorders/pkan/ — with comprehensive detail on pathophysiology, diagnosis, and management. For patients and families with confirmed or suspected PKAN, that page provides the full clinical picture. Within the neuroacanthocytosis framework, the key points are: PKAN is autosomal recessive; PANK2 genetic testing and the Eye of the Tiger MRI sign are the primary diagnostic tools; acanthocytes may be absent; and DBS is the most effective symptomatic treatment for the movement disorder components at KIMS.
What Are the Symptoms of Neuroacanthocytosis?
Across the core neuroacanthocytosis syndromes, the shared symptom picture reflects the progressive degeneration of the basal ganglia.
Movement Symptoms
Chorea — involuntary, flowing, unpredictable movements of the limbs, trunk, and face Orolingual dystonia — particularly in chorea-acanthocytosis — with tongue protrusion and self-biting Parkinsonism — slowness, rigidity, and postural instability in later stages Dystonia — abnormal sustained postures Tics and vocalizations in some patients
Cognitive and Psychiatric Symptoms
Personality change and disinhibition Cognitive slowing and executive dysfunction Depression and anxiety Obsessive-compulsive features In later stages, dementia
Neurological Complications
Seizures — particularly in chorea-acanthocytosis Peripheral neuropathy — with weakness and reduced reflexes Elevated serum creatine kinase (CK) — reflecting muscle involvement Dysphagia and dysarthria as the disease progresses
Cardiac Complications (McLeod Syndrome)
Dilated cardiomyopathy — enlargement and weakening of the heart muscle Cardiac arrhythmias — potentially life-threatening Requires regular echocardiography and Holter monitoring
The Self-Mutilation Feature — A Key Diagnostic Clue
The involuntary tongue and lip biting in chorea-acanthocytosis is severe enough to cause significant oral injury in many patients. Mouthguards and dental protection are an important practical management element. This feature is not seen in Huntington's Disease, Wilson's Disease, or most other movement disorders making it a highly specific clinical pointer to ChAc.
Diagnosis at KIMS
How Is Neuroacanthocytosis Diagnosed at KIMS?
Step 1: Clinical suspicion — the starting point
Neuroacanthocytosis should be considered in any patient aged 20–50 with a combination of: • Chorea or other involuntary movements • Progressive psychiatric or cognitive changes • Oral self-injury or orolingual dystonia • Seizures • Elevated serum CK without an obvious muscular cause • A family history suggesting autosomal recessive, autosomal dominant, or X-linked inheritance
Step 2: Peripheral blood smear — the simplest and most important initial test
A peripheral blood smear a drop of blood spread on a glass slide and examined under a microscope can identify acanthocytes. These abnormally shaped cells with irregular spike-like projections should be actively sought and reported. Acanthocytes may be absent in early disease or if the blood smear is not carefully prepared a negative smear does not absolutely exclude neuroacanthocytosis particularly in PKAN. At KIMS, we specifically request the peripheral smear in every young or middle-aged patient with unexplained chorea or basal ganglia disease. We communicate to the haematology laboratory the clinical suspicion so the smear is examined specifically for acanthocytes.
Step 3: Serum creatine kinase (CK)
Elevated CK reflecting muscle fibre damage is characteristic of chorea-acanthocytosis and McLeod syndrome. Its presence alongside a movement disorder and psychiatric symptoms strengthens the clinical suspicion.
Step 4: Brain MRI
MRI typically shows progressive atrophy shrinkage of the caudate nucleus and putamen the structures most severely affected in the basal ganglia degeneration of neuroacanthocytosis. This striatal atrophy visible on serial MRI scans is a characteristic feature that supports the diagnosis and helps distinguish it from Huntington's Disease which shows a similar but not identical MRI pattern.
Step 5: Genetic testing — the definitive investigation
Identification of the disease-specific gene mutation confirms the diagnosis and determines the subtype. At KIMS: • VPS13A chorein gene sequencing for chorea-acanthocytosis • XK gene sequencing for McLeod syndrome • JPH3 trinucleotide repeat analysis for HDL2 • PANK2 for PKAN Chorein immunoblotting a test that detects absence of the chorein protein in red blood cell membranes is a highly sensitive and specific test for chorea-acanthocytosis and can be used alongside genetic testing.
Step 6: Cardiac investigations (McLeod Syndrome)
For every patient with suspected or confirmed McLeod Syndrome ECG echocardiogram and 24-hour Holter monitoring are mandatory. Cardiac complications are a cause of death in McLeod syndrome and must not be overlooked.
Step 7: EMG and nerve conduction studies
Peripheral neuropathy in neuroacanthocytosis typically an axonal sensorimotor neuropathy is confirmed by nerve conduction studies and EMG. This also helps distinguish neuroacanthocytosis from Huntington's Disease which does not cause peripheral neuropathy.
Treatment
How Is Neuroacanthocytosis Treated at KIMS?
There are currently no treatments to prevent or slow the progression of neuroacanthocytosis. Treatment is symptomatic and supportive. Management at KIMS focuses on controlling the movement and psychiatric symptoms, preventing complications, and supporting the patient and family through a multidisciplinary programme.
Managing Chorea
Tetrabenazine a dopamine-depleting agent reduces chorea. Deutetrabenazine is a newer formulation with better tolerability. Low-dose antipsychotics can also reduce choreiform movements though must be used carefully given the risk of worsening dystonia and of late complications.
Managing Dystonia and Orolingual Movements
Botulinum toxin injections targeted at the muscles driving the most disabling dystonia can provide meaningful relief. For orolingual dystonia in chorea-acanthocytosis injections to specific facial and throat muscles combined with mouthguards for dental protection improve comfort and reduce injury.
Managing Seizures
Standard antiepileptic medications are used. Levetiracetam is typically preferred given its broad spectrum and relatively favourable side effect profile.
Managing Psychiatric Symptoms
SSRIs for depression and obsessive-compulsive features. Low-dose antipsychotics for severe agitation or psychosis used with caution given movement side effect risk.
Deep Brain Stimulation (DBS)
Some success has been reported with deep brain stimulation for neuroacanthocytosis particularly for the dystonic and choreiform components. It is not a standard treatment and the evidence base is limited to case series but for patients with severe treatment-refractory movement symptoms DBS discussion is appropriate. the KIMS Neuroscience team's DBS expertise at KIMS Neuroscience means this option can be systematically evaluated and offered when appropriate.
Cardiac Monitoring and Management (McLeod Syndrome)
Regular echocardiography and Holter monitoring are mandatory. If cardiomyopathy or significant arrhythmia develops cardiology co-management including consideration of implantable cardiac defibrillators is initiated.
Rehabilitation Therapies
Physiotherapy speech therapy and occupational therapy are integral to maintaining function and independence. Falls prevention swallowing management communication strategies and adaptive equipment for daily living are all relevant as the disease progresses.
Nutritional Support
Progressive orolingual dystonia in chorea-acanthocytosis significantly impairs eating. Dietary modification feeding equipment adaptations and ultimately gastrostomy tube feeding when oral nutrition becomes unsafe are planned proactively at KIMS never reactively after a nutritional crisis.
Genetic Counselling
Given the different inheritance patterns autosomal recessive ChAc X-linked recessive McLeod autosomal dominant HDL2 genetic counselling covers the implications for siblings children and other family members guided by the confirmed subtype and mutation.
When Should You Seek Specialist Assessment?
Seek specialist assessment at KIMS Neuroscience, Hyderabad if:
A young or middle-aged person has progressive involuntary movements alongside behavioural or cognitive changes
Involuntary tongue-thrusting or self-injurious lip or tongue biting is present this is a highly specific clinical flag for chorea-acanthocytosis
A person has been diagnosed with Huntington's Disease but the genetic test HTT repeat expansion was negative the condition may be neuroacanthocytosis or HDL2
A male patient has unexplained chorea alongside elevated CK or signs of cardiomyopathy McLeod syndrome should be investigated
An unexplained elevated serum CK is found alongside neurological or psychiatric symptoms in a young adult
What to Expect — Living with Neuroacanthocytosis
Neuroacanthocytosis syndromes are progressive. Affected individuals usually live for 10 to 20 years after disease onset. The rate of progression varies between subtypes and individuals. Management throughout this period focuses on symptom control, complication prevention, and maintaining quality of life.
For families in Hyderabad and across Telangana: the extreme rarity of neuroacanthocytosis means that most general neurologists have never seen a case. Specialist movement disorders assessment at KIMS Neuroscience with the targeted investigations, the genetic testing, and the multidisciplinary management gives patients the best available diagnostic certainty and the most appropriate management in South India.
Related Conditions
Neuroacanthocytosis is closely linked with several neurological and movement-related conditions that may present with similar symptoms or form part of the differential diagnosis:
FAQs
Frequently Asked Questions
Could it be Neuroacanthocytosis? Rare but critical to recognise.
Neuroacanthocytosis syndromes cause progressive movement disorders, psychiatric changes, and cognitive decline in young and middle aged individuals and are frequently misdiagnosed as more common conditions like Huntington's Disease. A simple peripheral blood smear can provide the crucial clue. Early recognition enables accurate diagnosis, appropriate genetic counselling, and better symptom management. You do not need a referral letter.
info@kimsneurosciences.com